1. Home
  2. News
Company News Media Coverage
HX9428 Achieves Positive Interim Results in Phase I/II Clinical Trial for nAMD
2026-09-17

HX9428 Achieves Positive Interim Results in Phase I/II Clinical Trial for nAMD

HX9428 for the treatment of neovascular age-related macular degeneration (“nAMD”) has completed the observation of the 24-week treatment data, and the Chinese Phase II dose-expansion study is still ongoing and interim clinical data have been obtained.
More
HX9428 Successfully Completed Phase I Clinical Study in Neovascular Age‑Related Macular Degeneration and Submitted Phase IIa IND Application for New Indication of Diabetic Macular Edema
2026-09-03

HX9428 Successfully Completed Phase I Clinical Study in Neovascular Age‑Related Macular Degeneration and Submitted Phase IIa IND Application for New Indication of Diabetic Macular Edema

HX9428, the candidate drug molecule of the innovative drug project HXP056 independently developed by the Company, formally submitted an Investigational New Drug application (IND) for a Phase IIa clinical trial for a new indication
More
Strengthening Global R&D | Dr. David Nicholson and Dr. Stephen Fawell Join Haixi Pharmaceuticals’ Scientific Advisory Board
2026-08-21

Strengthening Global R&D | Dr. David Nicholson and Dr. Stephen Fawell Join Haixi Pharmaceuticals’ Scientific Advisory Board

Fujian Haixi Pharmaceuticals Co., Ltd. (HKEX: 2637) is pleased to announce that Dr. David Nicholson and Dr. Stephen Fawell have joined the Company’s Scientific Advisory Board (SAB), further strengthening Haixi Pharmaceuticals’
More
HX9428 for the Treatment of Neovascular Age-Related Macular Degeneration Granted Fast Track Designation (FTD) by U.S. FDA
2026-08-18

HX9428 for the Treatment of Neovascular Age-Related Macular Degeneration Granted Fast Track Designation (FTD) by U.S. FDA

The board of directors of the Company is pleased to announce that HX9428, the candidate molecule of the innovative drug project HXP056 independently developed by the Company, was granted Fast Track Designation (“FTD”) by the U.S.
More
Haixi Pharma HX9428 Achieves New Breakthrough | U.S. FDA IND Approved, Parallel Phase II Clinical Trials Progress in China and the U.S.
2026-08-05

Haixi Pharma HX9428 Achieves New Breakthrough | U.S. FDA IND Approved, Parallel Phase II Clinical Trials Progress in China and the U.S.

the candidate molecule of HXP056, which was discovered and developed by the Company for the treatment of neovascular age-related macular degeneration ( nAMD), has been approved by the U.S. Food and Drug Administration (the “FDA”).
More
HXP089 Investigational New Drug (IND) Application for the Treatment of Glioblastoma Approved by National Medical Products Administration (NMPA)
2026-07-14

HXP089 Investigational New Drug (IND) Application for the Treatment of Glioblastoma Approved by National Medical Products Administration (NMPA)

HXP089 Investigational New Drug (IND) Application for the Treatment of Glioblastoma Approved by National Medical Products Administration (NMPA)
More
About Us
Technology
Products
News
Investor Relations
Careers
Contact Us

Fujian Haixi Pharmaceutical Co., Ltd. Fujian ICP Record No. 12015727 Internet Drug Information Service Qualification Certificate No.: (Min)-Non-operating-2023-0063

Some texts and images on this website are sourced from the Internet for sharing and learning purposes only. If any content infringes your rights and interests, please notify us promptly, and we will handle or remove the relevant materials without delay.